Global Tetanus Vaccine research

Tetanus Vaccine Comprehensive Study by Type (Tetanus Immune Globulin (TIG), Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin, Tetanus Toxoid (TT), Tetanus-Diphtheria (Td), Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP)), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Research organizations) Players and Region - Global Market Outlook to 2027

Tetanus Vaccine Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 5.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Tetanus Vaccine Market Scope
Tetanus is an illness which is caused by Clostridium bacteria characterized by muscle spasms. These spasms are severe and can cause a bone fracture. The symptoms may include fever, sweating, headache, hypertension, trouble swallowing and others. Tetanus vaccines are used for causing the body to produce its own protection. The general dosage recommended is five doses during childhood, sixth during adolescences with additional doses every 10 years.

According to AMA, the Global Tetanus Vaccine market is expected to see growth rate of 5.3%

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Tetanus Vaccine market throughout the predicted period.

Pfizer Inc.(United States), Sanofi (France), Serum Institute of India (India), BB-NCIPD (Bulgaria), GlaxoSmithKline (United Kingdom), PT Bio Farma (Indonesia) and Merck & Co. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Biological E (India), Shanha Biotechniques Pvt Ltd (India) and Shenzhen Kangtai Biological Products Co., Ltd. (China).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Tetanus Vaccine market by Type (Tetanus Immune Globulin (TIG), Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin, Tetanus Toxoid (TT), Tetanus-Diphtheria (Td) and Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP)), by Application (Hospitals, Clinics, Ambulatory Surgical Centers and Research organizations) and Region with country level break-up.

On the basis of geography, the market of Tetanus Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

According to WHO, In 2017 global demand of all D&T containing vaccines is estimated at 945M doses.4 DTwP-HepB-Hib (313M, 33%) and TT (252M, 27%) are the most used (out of 165 total vaccine types). Self-procuring countries represent half of the global demand (volume).
"According to WHO People of all ages can get tetanus but the disease is particularly common and serious in newborn babies and their mothers when the mothers` are unprotected from tetanus by the vaccine, tetanus toxoid."

Market Trend
  • Technology Advancement in

Market Drivers
  • Growing Government Support for Vaccine Development
  • Increased Awareness About The Disease Prevention And Treatment
  • Rising Focus on Immunization Programs

Opportunities
  • High Growth Prospects In Emerging Market

Restraints
  • Side Effects Associated With Vaccines Such As Redness and Pain At The Site of Injection, Fever and Fatigue & Muscles Pains

Challenges
  • Inadequate Access To Vaccines


Key Target Audience
Tetanus Vaccine Manufacturers & Suppliers, Research And Development (R&D) Companies, Hospitals And Clinics and Academic Institutes And Universities

Report Objectives / Segmentation Covered

By Type
  • Tetanus Immune Globulin (TIG)
  • Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin
  • Tetanus Toxoid (TT)
  • Tetanus-Diphtheria (Td)
  • Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP)
By Application
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Research organizations
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Government Support for Vaccine Development
      • 3.2.2. Increased Awareness About The Disease Prevention And Treatment
      • 3.2.3. Rising Focus on Immunization Programs
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Access To Vaccines
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement in
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tetanus Vaccine, by Type, Application and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Tetanus Vaccine (Value)
      • 5.2.1. Global Tetanus Vaccine by: Type (Value)
        • 5.2.1.1. Tetanus Immune Globulin (TIG)
        • 5.2.1.2. Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin
        • 5.2.1.3. Tetanus Toxoid (TT)
        • 5.2.1.4. Tetanus-Diphtheria (Td)
        • 5.2.1.5. Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP)
      • 5.2.2. Global Tetanus Vaccine by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Research organizations
      • 5.2.3. Global Tetanus Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Tetanus Vaccine (Volume)
      • 5.3.1. Global Tetanus Vaccine by: Type (Volume)
        • 5.3.1.1. Tetanus Immune Globulin (TIG)
        • 5.3.1.2. Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin
        • 5.3.1.3. Tetanus Toxoid (TT)
        • 5.3.1.4. Tetanus-Diphtheria (Td)
        • 5.3.1.5. Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP)
      • 5.3.2. Global Tetanus Vaccine by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Ambulatory Surgical Centers
        • 5.3.2.4. Research organizations
      • 5.3.3. Global Tetanus Vaccine Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Tetanus Vaccine (Price)
      • 5.4.1. Global Tetanus Vaccine by: Type (Price)
  • 6. Tetanus Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc.(United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Serum Institute of India (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BB-NCIPD (Bulgaria)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. PT Bio Farma (Indonesia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Tetanus Vaccine Sale, by Type, Application and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Tetanus Vaccine (Value)
      • 7.2.1. Global Tetanus Vaccine by: Type (Value)
        • 7.2.1.1. Tetanus Immune Globulin (TIG)
        • 7.2.1.2. Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin
        • 7.2.1.3. Tetanus Toxoid (TT)
        • 7.2.1.4. Tetanus-Diphtheria (Td)
        • 7.2.1.5. Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP)
      • 7.2.2. Global Tetanus Vaccine by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Research organizations
      • 7.2.3. Global Tetanus Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Tetanus Vaccine (Volume)
      • 7.3.1. Global Tetanus Vaccine by: Type (Volume)
        • 7.3.1.1. Tetanus Immune Globulin (TIG)
        • 7.3.1.2. Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin
        • 7.3.1.3. Tetanus Toxoid (TT)
        • 7.3.1.4. Tetanus-Diphtheria (Td)
        • 7.3.1.5. Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP)
      • 7.3.2. Global Tetanus Vaccine by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Ambulatory Surgical Centers
        • 7.3.2.4. Research organizations
      • 7.3.3. Global Tetanus Vaccine Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Tetanus Vaccine (Price)
      • 7.4.1. Global Tetanus Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tetanus Vaccine: by Type(USD Million)
  • Table 2. Tetanus Vaccine Tetanus Immune Globulin (TIG) , by Region USD Million (2016-2021)
  • Table 3. Tetanus Vaccine Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin , by Region USD Million (2016-2021)
  • Table 4. Tetanus Vaccine Tetanus Toxoid (TT) , by Region USD Million (2016-2021)
  • Table 5. Tetanus Vaccine Tetanus-Diphtheria (Td) , by Region USD Million (2016-2021)
  • Table 6. Tetanus Vaccine Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP) , by Region USD Million (2016-2021)
  • Table 7. Tetanus Vaccine: by Application(USD Million)
  • Table 8. Tetanus Vaccine Hospitals , by Region USD Million (2016-2021)
  • Table 9. Tetanus Vaccine Clinics , by Region USD Million (2016-2021)
  • Table 10. Tetanus Vaccine Ambulatory Surgical Centers , by Region USD Million (2016-2021)
  • Table 11. Tetanus Vaccine Research organizations , by Region USD Million (2016-2021)
  • Table 12. South America Tetanus Vaccine, by Country USD Million (2016-2021)
  • Table 13. South America Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 14. South America Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 15. Brazil Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 16. Brazil Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 17. Argentina Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 18. Argentina Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 19. Rest of South America Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 20. Rest of South America Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 21. Asia Pacific Tetanus Vaccine, by Country USD Million (2016-2021)
  • Table 22. Asia Pacific Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 23. Asia Pacific Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 24. China Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 25. China Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 26. Japan Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 27. Japan Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 28. India Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 29. India Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 30. South Korea Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 31. South Korea Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 32. Taiwan Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 33. Taiwan Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 34. Australia Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 35. Australia Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 36. Rest of Asia-Pacific Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 37. Rest of Asia-Pacific Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 38. Europe Tetanus Vaccine, by Country USD Million (2016-2021)
  • Table 39. Europe Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 40. Europe Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 41. Germany Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 42. Germany Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 43. France Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 44. France Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 45. Italy Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 46. Italy Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 47. United Kingdom Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 48. United Kingdom Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 49. Netherlands Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 50. Netherlands Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 51. Rest of Europe Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 52. Rest of Europe Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 53. MEA Tetanus Vaccine, by Country USD Million (2016-2021)
  • Table 54. MEA Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 55. MEA Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 56. Middle East Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 57. Middle East Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 58. Africa Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 59. Africa Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 60. North America Tetanus Vaccine, by Country USD Million (2016-2021)
  • Table 61. North America Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 62. North America Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 63. United States Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 64. United States Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 65. Canada Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 66. Canada Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 67. Mexico Tetanus Vaccine, by Type USD Million (2016-2021)
  • Table 68. Mexico Tetanus Vaccine, by Application USD Million (2016-2021)
  • Table 69. Tetanus Vaccine Sales: by Type(K )
  • Table 70. Tetanus Vaccine Sales Tetanus Immune Globulin (TIG) , by Region K (2016-2021)
  • Table 71. Tetanus Vaccine Sales Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin , by Region K (2016-2021)
  • Table 72. Tetanus Vaccine Sales Tetanus Toxoid (TT) , by Region K (2016-2021)
  • Table 73. Tetanus Vaccine Sales Tetanus-Diphtheria (Td) , by Region K (2016-2021)
  • Table 74. Tetanus Vaccine Sales Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP) , by Region K (2016-2021)
  • Table 75. Tetanus Vaccine Sales: by Application(K )
  • Table 76. Tetanus Vaccine Sales Hospitals , by Region K (2016-2021)
  • Table 77. Tetanus Vaccine Sales Clinics , by Region K (2016-2021)
  • Table 78. Tetanus Vaccine Sales Ambulatory Surgical Centers , by Region K (2016-2021)
  • Table 79. Tetanus Vaccine Sales Research organizations , by Region K (2016-2021)
  • Table 80. South America Tetanus Vaccine Sales, by Country K (2016-2021)
  • Table 81. South America Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 82. South America Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 83. Brazil Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 84. Brazil Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 85. Argentina Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 86. Argentina Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 87. Rest of South America Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 88. Rest of South America Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 89. Asia Pacific Tetanus Vaccine Sales, by Country K (2016-2021)
  • Table 90. Asia Pacific Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 91. Asia Pacific Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 92. China Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 93. China Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 94. Japan Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 95. Japan Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 96. India Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 97. India Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 98. South Korea Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 99. South Korea Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 100. Taiwan Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 101. Taiwan Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 102. Australia Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 103. Australia Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 104. Rest of Asia-Pacific Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 105. Rest of Asia-Pacific Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 106. Europe Tetanus Vaccine Sales, by Country K (2016-2021)
  • Table 107. Europe Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 108. Europe Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 109. Germany Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 110. Germany Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 111. France Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 112. France Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 113. Italy Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 114. Italy Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 115. United Kingdom Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 116. United Kingdom Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 117. Netherlands Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 118. Netherlands Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 119. Rest of Europe Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 120. Rest of Europe Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 121. MEA Tetanus Vaccine Sales, by Country K (2016-2021)
  • Table 122. MEA Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 123. MEA Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 124. Middle East Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 125. Middle East Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 126. Africa Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 127. Africa Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 128. North America Tetanus Vaccine Sales, by Country K (2016-2021)
  • Table 129. North America Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 130. North America Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 131. United States Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 132. United States Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 133. Canada Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 134. Canada Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 135. Mexico Tetanus Vaccine Sales, by Type K (2016-2021)
  • Table 136. Mexico Tetanus Vaccine Sales, by Application K (2016-2021)
  • Table 137. Tetanus Vaccine: by Type(USD/Units)
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Tetanus Vaccine: by Type(USD Million)
  • Table 146. Tetanus Vaccine Tetanus Immune Globulin (TIG) , by Region USD Million (2022-2027)
  • Table 147. Tetanus Vaccine Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin , by Region USD Million (2022-2027)
  • Table 148. Tetanus Vaccine Tetanus Toxoid (TT) , by Region USD Million (2022-2027)
  • Table 149. Tetanus Vaccine Tetanus-Diphtheria (Td) , by Region USD Million (2022-2027)
  • Table 150. Tetanus Vaccine Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP) , by Region USD Million (2022-2027)
  • Table 151. Tetanus Vaccine: by Application(USD Million)
  • Table 152. Tetanus Vaccine Hospitals , by Region USD Million (2022-2027)
  • Table 153. Tetanus Vaccine Clinics , by Region USD Million (2022-2027)
  • Table 154. Tetanus Vaccine Ambulatory Surgical Centers , by Region USD Million (2022-2027)
  • Table 155. Tetanus Vaccine Research organizations , by Region USD Million (2022-2027)
  • Table 156. South America Tetanus Vaccine, by Country USD Million (2022-2027)
  • Table 157. South America Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 158. South America Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 159. Brazil Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 160. Brazil Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 161. Argentina Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 162. Argentina Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 163. Rest of South America Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 164. Rest of South America Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 165. Asia Pacific Tetanus Vaccine, by Country USD Million (2022-2027)
  • Table 166. Asia Pacific Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 167. Asia Pacific Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 168. China Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 169. China Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 170. Japan Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 171. Japan Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 172. India Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 173. India Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 174. South Korea Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 175. South Korea Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 176. Taiwan Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 177. Taiwan Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 178. Australia Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 179. Australia Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 180. Rest of Asia-Pacific Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 181. Rest of Asia-Pacific Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 182. Europe Tetanus Vaccine, by Country USD Million (2022-2027)
  • Table 183. Europe Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 184. Europe Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 185. Germany Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 186. Germany Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 187. France Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 188. France Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 189. Italy Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 190. Italy Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 191. United Kingdom Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 192. United Kingdom Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 193. Netherlands Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 194. Netherlands Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 195. Rest of Europe Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 196. Rest of Europe Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 197. MEA Tetanus Vaccine, by Country USD Million (2022-2027)
  • Table 198. MEA Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 199. MEA Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 200. Middle East Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 201. Middle East Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 202. Africa Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 203. Africa Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 204. North America Tetanus Vaccine, by Country USD Million (2022-2027)
  • Table 205. North America Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 206. North America Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 207. United States Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 208. United States Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 209. Canada Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 210. Canada Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 211. Mexico Tetanus Vaccine, by Type USD Million (2022-2027)
  • Table 212. Mexico Tetanus Vaccine, by Application USD Million (2022-2027)
  • Table 213. Tetanus Vaccine Sales: by Type(K )
  • Table 214. Tetanus Vaccine Sales Tetanus Immune Globulin (TIG) , by Region K (2022-2027)
  • Table 215. Tetanus Vaccine Sales Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin , by Region K (2022-2027)
  • Table 216. Tetanus Vaccine Sales Tetanus Toxoid (TT) , by Region K (2022-2027)
  • Table 217. Tetanus Vaccine Sales Tetanus-Diphtheria (Td) , by Region K (2022-2027)
  • Table 218. Tetanus Vaccine Sales Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP) , by Region K (2022-2027)
  • Table 219. Tetanus Vaccine Sales: by Application(K )
  • Table 220. Tetanus Vaccine Sales Hospitals , by Region K (2022-2027)
  • Table 221. Tetanus Vaccine Sales Clinics , by Region K (2022-2027)
  • Table 222. Tetanus Vaccine Sales Ambulatory Surgical Centers , by Region K (2022-2027)
  • Table 223. Tetanus Vaccine Sales Research organizations , by Region K (2022-2027)
  • Table 224. South America Tetanus Vaccine Sales, by Country K (2022-2027)
  • Table 225. South America Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 226. South America Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 227. Brazil Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 228. Brazil Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 229. Argentina Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 230. Argentina Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 231. Rest of South America Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 232. Rest of South America Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 233. Asia Pacific Tetanus Vaccine Sales, by Country K (2022-2027)
  • Table 234. Asia Pacific Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 235. Asia Pacific Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 236. China Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 237. China Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 238. Japan Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 239. Japan Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 240. India Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 241. India Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 242. South Korea Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 243. South Korea Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 244. Taiwan Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 245. Taiwan Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 246. Australia Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 247. Australia Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 248. Rest of Asia-Pacific Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 249. Rest of Asia-Pacific Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 250. Europe Tetanus Vaccine Sales, by Country K (2022-2027)
  • Table 251. Europe Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 252. Europe Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 253. Germany Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 254. Germany Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 255. France Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 256. France Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 257. Italy Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 258. Italy Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 259. United Kingdom Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 260. United Kingdom Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 261. Netherlands Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 262. Netherlands Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 263. Rest of Europe Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 264. Rest of Europe Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 265. MEA Tetanus Vaccine Sales, by Country K (2022-2027)
  • Table 266. MEA Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 267. MEA Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 268. Middle East Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 269. Middle East Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 270. Africa Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 271. Africa Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 272. North America Tetanus Vaccine Sales, by Country K (2022-2027)
  • Table 273. North America Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 274. North America Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 275. United States Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 276. United States Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 277. Canada Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 278. Canada Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 279. Mexico Tetanus Vaccine Sales, by Type K (2022-2027)
  • Table 280. Mexico Tetanus Vaccine Sales, by Application K (2022-2027)
  • Table 281. Tetanus Vaccine: by Type(USD/Units)
  • Table 282. Research Programs/Design for This Report
  • Table 283. Key Data Information from Secondary Sources
  • Table 284. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tetanus Vaccine: by Type USD Million (2016-2021)
  • Figure 5. Global Tetanus Vaccine: by Application USD Million (2016-2021)
  • Figure 6. South America Tetanus Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Tetanus Vaccine Share (%), by Country
  • Figure 8. Europe Tetanus Vaccine Share (%), by Country
  • Figure 9. MEA Tetanus Vaccine Share (%), by Country
  • Figure 10. North America Tetanus Vaccine Share (%), by Country
  • Figure 11. Global Tetanus Vaccine: by Type K (2016-2021)
  • Figure 12. Global Tetanus Vaccine: by Application K (2016-2021)
  • Figure 13. South America Tetanus Vaccine Share (%), by Country
  • Figure 14. Asia Pacific Tetanus Vaccine Share (%), by Country
  • Figure 15. Europe Tetanus Vaccine Share (%), by Country
  • Figure 16. MEA Tetanus Vaccine Share (%), by Country
  • Figure 17. North America Tetanus Vaccine Share (%), by Country
  • Figure 18. Global Tetanus Vaccine: by Type USD/Units (2016-2021)
  • Figure 19. Global Tetanus Vaccine share by Players 2021 (%)
  • Figure 20. Global Tetanus Vaccine share by Players (Top 3) 2021(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Pfizer Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc.(United States) Revenue: by Geography 2021
  • Figure 24. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 25. Sanofi (France) Revenue: by Geography 2021
  • Figure 26. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 27. Serum Institute of India (India) Revenue: by Geography 2021
  • Figure 28. BB-NCIPD (Bulgaria) Revenue, Net Income and Gross profit
  • Figure 29. BB-NCIPD (Bulgaria) Revenue: by Geography 2021
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2021
  • Figure 32. PT Bio Farma (Indonesia) Revenue, Net Income and Gross profit
  • Figure 33. PT Bio Farma (Indonesia) Revenue: by Geography 2021
  • Figure 34. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck & Co. (United States) Revenue: by Geography 2021
  • Figure 36. Global Tetanus Vaccine: by Type USD Million (2022-2027)
  • Figure 37. Global Tetanus Vaccine: by Application USD Million (2022-2027)
  • Figure 38. South America Tetanus Vaccine Share (%), by Country
  • Figure 39. Asia Pacific Tetanus Vaccine Share (%), by Country
  • Figure 40. Europe Tetanus Vaccine Share (%), by Country
  • Figure 41. MEA Tetanus Vaccine Share (%), by Country
  • Figure 42. North America Tetanus Vaccine Share (%), by Country
  • Figure 43. Global Tetanus Vaccine: by Type K (2022-2027)
  • Figure 44. Global Tetanus Vaccine: by Application K (2022-2027)
  • Figure 45. South America Tetanus Vaccine Share (%), by Country
  • Figure 46. Asia Pacific Tetanus Vaccine Share (%), by Country
  • Figure 47. Europe Tetanus Vaccine Share (%), by Country
  • Figure 48. MEA Tetanus Vaccine Share (%), by Country
  • Figure 49. North America Tetanus Vaccine Share (%), by Country
  • Figure 50. Global Tetanus Vaccine: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc.(United States)
  • Sanofi (France)
  • Serum Institute of India (India)
  • BB-NCIPD (Bulgaria)
  • GlaxoSmithKline (United Kingdom)
  • PT Bio Farma (Indonesia)
  • Merck & Co. (United States)
Additional players considered in the study are as follows:
Biological E (India) , Shanha Biotechniques Pvt Ltd (India) , Shenzhen Kangtai Biological Products Co., Ltd. (China)
Select User Access Type

Key Highlights of Report


Mar 2022 211 Pages 80 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tetanus Vaccine research Quantitative research analysis
Global Tetanus Vaccine research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Tetanus Vaccine study can be customized to meet your requirements. The market size breakdown by type [Tetanus Immune Globulin (TIG), Intravenous Immune Globulin (IVIG) Containing Tetanus Antitoxin, Tetanus Toxoid (TT), Tetanus-Diphtheria (Td) and Diphtheria Toxoid And Acellular Pertussis Vaccine (DTaP)], by end use application [Hospitals, Clinics, Ambulatory Surgical Centers and Research organizations].
The Tetanus Vaccine Market is gaining popularity and expected to see strong valuation by 2027.
According to AMA, the Global Tetanus Vaccine market is expected to see growth rate of 5.3%.

Know More About Global Tetanus Vaccine research Report?

Have a Query? Click Here

Other Related Reports

Thoracic Drainage Devices Comprehensive Study by Type (Thoracic Drainage Systems, Thoracic Drainage Kits, Pleural Drainage Catheters, Trocar Drains, Others), Application (Cardiac Surgery, Oncology & ...
$ 3750
Medical Blades Comprehensive Study by Type (Stainless Steel, High Grade Carbon Steel), Application (Cardiothoracic Surgery, Gastrointestinal surgery, Orthopedic Surgery, Gynecological Surgery, Vascul...
$ 3750
Hematology Analyzers Comprehensive Study by Type (5 Parts, 6 Parts, 3 Part, PoC, Semi-Automated), Application (Hospital, Laboratory), Price (High, Low) Players and Region - Global Market Outlook to 2...
$ 3500
Ileostomy Comprehensive Study by Type (End Ileostomy, Loop Ileostomy), Application (Cancer, Diverticulitis, Ulcerative Colitis, Crohn's Disease, Others), End Users (Hospitals, Ambulatory Surgical Cen...
$ 3450
Joint Replacement Comprehensive Study by Area of Treatment (Hip, Knee, Elbow, Ankle, Others), Replacement Type (Total Replacement, Partial Replacement, Revision Replacement), End User (Hospitals, Or...
$ 3350
Artificial Heart Valve Comprehensive Study by Type (Transcatheter Heart Valves, Tissue Heart Valves, Mechanical Heart Valves), Application (Hospitals, Surgery Centers), Valve (Aortic Valve, Mitral Va...
$ 3500